^
1d
A Clinical Study of MK-1084 With Rosuvastatin and Metformin in Healthy People (MK-1084-016) (clinicaltrials.gov)
P1, N=16, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
Enrollment open
|
metformin • MK-1084
6d
New P2 trial
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed • MK-1084
1m
New P1 trial
|
metformin • MK-1084
1m
New P1 trial
|
MK-1084
1m
Enrollment open
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • MK-1084
1m
Trial completion
|
MK-1084
2ms
New P2 trial • Pan tumor
|
KRAS (KRAS proto-oncogene GTPase)
|
Erbitux (cetuximab) • MK-1084
2ms
New P3 trial
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • MK-1084
4ms
Trial completion date
|
KRAS (KRAS proto-oncogene GTPase)
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • MK-1084 • levoleucovorin calcium
4ms
Enrollment open
|
KRAS (KRAS proto-oncogene GTPase)
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • MK-1084 • levoleucovorin calcium
6ms
A Study to Evaluate the Effect of Formulation and Food on MK-1084 in Healthy Adult Participants (MK-1084-011) (clinicaltrials.gov)
P1, N=52, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
Enrollment closed
|
MK-1084
6ms
New P3 trial
|
KRAS (KRAS proto-oncogene GTPase)
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • MK-1084 • levoleucovorin calcium